anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A device to enhance and present a medical image using a corrective mechanism is described. An image analysis application executed by the device captures a digital copy of the medical image displayed on a display device. A flawed photography effect associated with the digital copy is identified by processing the digital copy. Next, the digital copy is enhanced based on the flawed photography effect. Furthermore, the enhanced digital copy can be processed with an artificial intelligence mechanism to generate an annotation. The annotation is associated with a cancer identification. In addition, the enhanced digital copy and the annotation are displayed.
PURPOSE:A promoter for blood coagulation for coagulating blood in a short time, having improved separating properties of serum from blood-clot, containing a metallic complex having a specific organic compound as a ligand and a hydrolase. CONSTITUTION:A promoter for blood coagulation containing (A) 100pts.wt. metallic complex having a cyclic organic compound which is shown by the formula (A is cyclic compound residue) where neighboring carbonyl groups substantially exist in the same plane as a ligand, as an activator for blood coagulation factor and (B) 0.01-100pts.wt. hydrolase (e.g. serine protease, thiol protease or metallic proteas) capable of hydrolyzing a bond between Arg and any amino acid residue and/or bond between Lys and any amino acid residue in peptide chain. A compound containing o-quinone, gallic acid alkyl ester, 1,2,3-triketo-hydroindene, isatin, etc., may be cited as the compound shown by the formula.
PURPOSE:To surely prevent the vigorous generation of bubbles right after injection of a soln. and to enhance the ease of use by providing the fibrinogen-contg. pharmaceutical which is the constituting component of a tissue adhesive existing as two-component pharmaceuticals after freezing drying the pharmaceutical and hermetically sealing the pharmaceutical under a reduced pressure. CONSTITUTION:The human fibrinogen prepd. by the conventional method, for example, by subjecting the cryoprecipitate obtd. from the frozen original blood plasma to glycine fractionation and ethanol fractionation, etc., is dissolved at about 2% into, for example, 0.005mol/l sldium citrate-0.075mol/1NaCl buffer soln. and is then subjected to sterile filtration. After 12ml volume each of such fibrinogen is dispensed and is freeze dried, the fibrinogen is hermetically sealed under a reduced pressure of about 10<-2>mm Hg degree of pressure reduction. The prepn. is dissolved in about 3ml aprotinic acid (about 1000 unit/ml) activity and is then so treated as to restore the atm. pressure by using a draft gage. The bubbles are instantaneously annihilated at this time.
Congenital deafness enhances responses of auditory cortices to non-auditory tasks, yet the nature of the reorganization is not well understood. Here, naturalistic stimuli are used to induce neural synchrony across early deaf and hearing individuals. Participants watch a silent animated film in an intact version and three versions with gradually distorted meaning. Differences between groups are observed in higher-order auditory cortices in all stimuli, with no statistically significant effects in the primary auditory cortex. Comparison between levels of scrambling revealed a heterogeneity of function in secondary auditory areas. Both hemispheres show greater synchrony in the deaf than in the hearing participants for the intact movie and high-level variants. However, only the right hemisphere shows an increased inter-subject synchrony in the deaf people for the low-level movie variants. An event segmentation validates these results: the dynamics of the right secondary auditory cortex in the deaf people consist of shorter-length events with more transitions than the left. Our results reveal how deaf individuals use their auditory cortex to process visual meaning.
mHealth interventions play an increasingly important role in health behavior change for gestational diabetes or peripartum obesity management. This qualitative systematic review and meta-synthesis aims to explore women's perceptions of mHealth behavior change interventions for gestational diabetes and/or overweight/obesity management during pregnancy and the postpartum period. Cumulative Index of Nursing and Allied Health Literature (CINAHL), Cochrane, Excerpta Medica Database (EMBASE), Medical Literature Analysis and Retrieval System Online (MEDLINE), and Psychological Information Database (PsycINFO) databases were searched using a Sample, Phenomenon of Interest, Design, Evaluation and Research type (SPIDER) concept framework through to February 2024. Included studies were quality assessed using the Critical Appraisal Skills Programme checklist. Study findings were evaluated using reflexive thematic analysis and GRADE-Confidence in the Evidence from Reviews of Qualitative Research (CERQual) checklist. We identified 29 studies, representing 604 women's views from one upper middle-income and nine high-income countries. Two themes were generated: mHealth as a supportive tool; and mHealth as a personalizable tool. Women highlighted the importance of self-monitoring, information trustworthiness, peer support, motivational tools (goal setting, risk awareness, and problem solving) and convenience in achieving behavior change using mHealth technology. They suggest mHealth programs incorporate these elements to support user engagement and improved health outcomes. Understanding what women want as mHealth users is particularly important for effective interventions in gestational diabetes, weight management, and chronic disease prevention. Creating a better, more woman-centered experience by addressing central engagement issues should result in improved maternal health outcomes.
Consecutive 93 patients undergoing inguinal herniorrhaphy will be recruited with a prospective protocol.Spinal anesthesia will be commenced in Group BLS with 2 ml hyperbaric bupivacaine (10 mg) + 0.6 ml 1 % lidocaine (6 mg), in Group BS, hyperbaric bupivacaine (10 mg) + saline in the same volume and Group LIA will have anesthesia with bupivacaine and lidocaine for step by step local anesthetic infiltration. Sensorial block will be measured with pinprick test, motor block will be tested with Bromage scale. Heart rate, blood pressure and peripheral oxygen saturation will be measured every 5 minutes. Time of subarachnoid injection, onset of sensorial block (block at L1 dermatome), time to block T10 dermatome, maximum block level, time to maximum block and time to two segment regression, T10 regression , LI regression and S1 regression of the block will be recorded in group BLS and BS.The onset and resolution of the sensorial and motor block will be assessed by anesthetists blinded to group allocation. PACU stay and discharge times and VAS pain scores will be recorded in all patients. Patients also will be investigated for adverse events (hypotension, bradycardia, nausea,PDPH, TNS, urinary retention)and satisfaction regarding the anesthetic method.
Hyperuricemia (HUA) is a metabolic disease characterized by the increase of serum uric acid (UA) level. Sargentodoxae Caulis (SC) is a commonly used herbal medicine for the treatment of gouty arthritis, traumatic swelling, and rheumatic arthritis in clinic. In this study, a total of fifteen compounds were identified in SC water extract using UHPLC-Q-TOF-MS/MS, including three phenolic acids, seven phenolic glycosides, four organic acids, and one lignan. Then, to study the hypouricemia effect of SC, a HUA mouse model was induced using a combination of PO, HX, and 20% yeast feed. After 14 days of treatment with the SC water extract, the levels of serum UA, creatinine (CRE), blood urea nitrogen (BUN) were reduced significantly, and the organ indexes were restored, the xanthine oxidase (XOD) activity were inhibited as well. Meanwhile, SC water extract could ameliorate the pathological status of kidneys and intestine of HUA mice. Additionally, quantitative real-time PCR (qRT-PCR) and western blotting results showed that SC water extract could increase the expression of ATP binding cassette subfamily G member 2 (ABCG2), organic cation transporter 1 (OCT1), organic anion transporter 1 (OAT1) and organic anion transporter 3 (OAT3), whereas decrease the expression of glucose transporter 9 (GLUT9). This study provided a data support for the clinical application of SC in the treatment of HUA.
FIELD: medicine. ^ SUBSTANCE: invention relates to veterinary medicine, namely to medications (preparations) from medicinal plants. Medication for prevention of development and treatment of inflammatory processes in animals, characterised by the fact that it represents mixture of crushed to small and tiny particles processed by ultraviolet rays of lamps following medicinal plants with dosage 15.0 g (0.5 wt %): dried stems, leaves, flowers of peppermint, dried flowers of chamomile, dried leaves of plantain, dried heads of tansy, dried stems, leaves, flowers, fruit of melilotus officinalis, dried grass of hypericum perforatum, dried flowers of pot marigold (calendula), dried grass of yarrow, dried grass of thyme, dried stems, leaves, flowers, fruit of wartwort, dried leaves of eucalyptus, dried leaves and flower heads of coltsfoot, dried leaves of sage, dried leaves of nettle, dried grass of redshank, dried flowers of corolla of denseflower mullein, crushed fruit of anise and wild brown rose, crushed kernels of walnut, seedless pulp of sea buckthorn fruit, which is placed into dry sterile dark glass vessel, 800 g (10 wt %) of plant raw material are mixed with 2700.0 g (90 wt %) of 0.9% by sodium chloride of sterile table salt, mixture with stirring is left at room temperature for up to 1.5 days, after that it vessel with mixture is placed into water bath for up to 10 hours with mixture temperature up to 42C with stirring, after that liquid part is separated from plant raw material. Preparation is stored in vessels from dark glass or in dark place at temperature below plus 4C for up to 25 days, before intake by animal it is shaken, heated, given as it is or diluted with boiled water with ratio 1:1.5-2. ^ EFFECT: invention ensures enhanced efficiency of prevention of development and treatment of inflammatory processed in animals. ^ 2 cl
RATIONALE: Multilocular cystic hemangioma is a rare benign tumor classified as an atypical hemangioma. Currently, there are limited imaging reports available, and the imaging characteristics can be challenging to distinguish from other malignant multilocular cystic liver diseases such as cystadenocarcinoma, necessitating confirmation through pathological diagnosis. Here, we discuss the imaging features of 3 cases of multilocular cystic hemangiomas.
PATIENT CONCERNS AND DIAGNOSES: Case 1 was a 24-year-old young female, and Case 2 involved a 60-year-old elderly male. Both patients were asymptomatic and physical examination revealed hepatic space-occupying lesions. Imaging findings revealed multilocular cystic lesions in the left liver with septa, calcification, a high diffusion-weighted magnetic resonance imaging (DWI) signal at the edge of the lesion, and progressive enhancement of the cyst wall and septa. Case 3 involved a 50-year-old male patient with epigastric distending pain for 1 month and sudden severe abdominal pain for 14 hours. Imaging results revealed a multilocular cystic lesion in the left liver with septa and tumor bleeding, a high DWI signal, and an enhanced cyst wall and septa. The pathological diagnosis confirmed a hepatic hemangioma.
INTERVENTIONS: All 3 patients underwent liver tumor resection.
OUTCOMES: All 3 patients recovered successfully without any intraoperative or postoperative complications during the follow-up periods of 5 years, 6 months, and 5 months. There were no signs of recurrence.
LESSONS: Liver imaging revealed multilocular cystic lesions with features, such as compartmentalization, calcification, or bleeding. Multilocular cystic hemangiomas should be considered in imaging diagnosis. Enhancing our understanding of multilocular cystic hemangiomas can aid in improving the differential diagnosis of other malignant multilocular cystic liver diseases, ultimately reducing unnecessary liver resection.
This is a Phase 1b, dose-escalation, open-label study in subjects with HER2 expressing solid tumors. Subjects will receive escalating doses of ADXS31-164 every 3 weeks during a 12-week treatment cycle. Subjects will receive a prophylactic regimen completed at least 30 minutes prior to each ADXS31-164 infusion to mitigate and manage the potential immune response seen with immunotherapy administration. In addition, all subjects will participate in a 3 year Lm surveillance period. The surveillance period will begin following the last dose of study treatment or at the time of study discontinuation. This period is intended to help ensure the eradication of Lm bacteria. This period will also include a 6- month course of trimethoprim/sulfamethoxazole which will be initiated approximately 72 hours after the completion of the last dose of ADXS31-164 or immediately following study discontinuation. In subjects with a sulfa allergy, the 6-month course should consist of ampicillin 500 mg 4 times daily initiated approximately 72 hours following the last dose of study treatment or immediately following study discontinuation.

Dose escalations and de-escalations will be dictated by a 3+3 design. Three dose levels may be evaluated during the dose escalation portion starting with Dose Level 1 at 1 x 109 colony forming units (CFU). Once the Maximum Tolerated Dose (MTD) and RP2D have been identified, up to 4 HER2 overexpressing tumor specific expansion cohorts will be evaluated. The specific tumor types included in the expansion cohorts may include breast and gastric cancer with the remaining to be determined by the sponsor after review of data from Part A. Treatment cycles can be repeated at the RP2D (or less) for each subject for up to 2 years, until a study discontinuation criterion is met or he/she has completed \>6 months of study therapy and at least 1 cycle of treatment post observation of a complete response (CR)
This group consists of young adults aged 18-25 who have been diagnosed with temporomandibular joint (TMJ) dysfunction. The diagnosis was determined using the Fonseca Amnestic Index, where participants with a score greater than 20 were classified into this group. The participants in this group are being analyzed for proprioception, body awareness, and pain-related parameters, including pain threshold, pain tolerance, and temporal summation.
Valsartan – Hydrochlorothiazide: In the controlled trials of various doses of Diovan HCT the incidence of hypertensive patients who developed hypokalemia (serum potassium <3.5 mEq/L) was 3.0%; the incidence of hyperkalemia (serum potassium >5.7 mEq/L) was 0.4%.

Hydrochlorothiazide can cause hypokalemia and hyponatremia. Hypomagnesemia can result in hypokalemia which appears difficult to treat despite potassium repletion. Drugs that inhibit the renin-angiotensin system can cause hyperkalemia. Monitor serum electrolytes periodically. 

If hypokalemia is accompanied by clinical signs (e.g. muscular weakness, paresis, or ECG alterations), Diovan HCT should be discontinued. Correction of hypokalemia and any coexisting hypomagnesemia is recommended prior to the initiation of thiazides.

Some patients with heart failure have developed increases in potassium with Diovan therapy. These effects are usually minor and transient, and they are more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or Diovan may be required [see Adverse Reactions (6.1)].
The invention discloses blood glucose reducing powder. The blood glucose reducing powder with the special efficiency solves the problem that a diabetes patient needs to take medicine for life. Dependency of hypoglycemic drugs which need to be taken for a long time is solved completely, and the blood glucose reducing powder is not prone to reappearing and free from toxic and side effects. The blood glucose reducing powder comprises, by weight, 50 parts of saururus chinensis, 20 parts of yellow stilbene, 10 parts of red ginseng, 5 parts of radix scrophulariae, 5 parts of cortex moutan, 3 parts of cartialgenous and 7 parts of gizzard-membrane, wherein the saururus chinensis, the stilbene, the red ginseng, the radix scrophulariae, the cortex moutan, the cartialgenous and the gizzard-membrane. A preparation method comprises that the raw materials are dried under high temperature, sterilized and mixed, and then are placed into a medicine grinder so as to be grinded. The raw materials are sieved for 80 meshes to 100 meshes, and prepared powder is placed in a container. The container is placed in a shade place so as to be stored, and the powder is placed in non-toxic plastic bags and sealed after 12 hours, the weight of each bag of powder is 500g. The using method comprises that the 5g of the powder is taken each time, three times a day, and the powder needs to be swallowed with boiled water half an hour before dinner. A course of treatment lasts for two months, the diabetes patient can recover after three courses of treatment and the diabetes can not reappear.
OBJECTIVES: Management of the neck in patients with oral squamous cell carcinoma (OSCC) is pivotal to oncologic control and survival. However, there is controversy regarding necessity of neck dissection (ND) in patients with clinically node-negative neck. We aimed to assess risk factors for occult metastasis and to explore whether the presence of occult lymph node metastases (LNMs) has an impact on recurrence and survival.
MATERIAL AND METHODS: A retrospective cohort study was performed including patients with primary OSCC who underwent radical tumor resection and ND in a high-volume center adhering to the prevailing German guideline. The ND was performed according to a standardized approach.
RESULTS: Four hundred twenty-one patients with primary surgically treated OSCC were included. The incidence of occult metastasis was 14.49%. A pathological T stage > 1 (multivariate analysis, odds ratio (OR) 3.958, p = 0.042) and the presence of extranodal extension in LNMs (multivariate analysis, OR 0.287, p = 0.020) were identified as independent risk factors for occult metastasis. When comparing patients with and without occult metastasis, there were no significant differences in terms of progression-free survival (log-rank, p = 0.297) and overall survival (log-rank, p = 0.320). There were no cases of ipsilateral neck recurrence. One patient developed contralateral neck metastasis; however, he initially presented with a unilateral pT1 pN0 tumor.
CONCLUSIONS: Overall, our findings suggest that conducting a standardized approach in ND should be applied in terms of management of the neck in order to maintain survival rates and to prevent neck recurrence in OSCC patients.
CLINICAL RELEVANCE: None of the risk factors for occult metastasis can be reliably assessed preoperatively. Although elective ND does not guarantee the complete prevention of neck recurrence, it increases the likelihood of either timely removal of micrometastases or strengthens the justification for adjuvant therapy. Consequently, this approach leads to improvements in clinical outcomes.
Mechanical dispersion processes previously used to produce liposomes and emulsions have limitations with respect to reproducible production of large amounts of dispersion. The conventional processes mostly operate discontinuously and only allow the production of small amounts of product (laboratory scale) having low concentrations of disperse phase. The high-pressure extrusion process according to the invention, in contrast, enables continuous production of highly concentrated dispersions in the pharmaceutically acceptable quality. The properties of the dispersions obtained can be set over a broad range and are also reproducible in the production of large amounts of product. In the process according to the invention, appropriate predispersions are continuously extruded at high pressure (> 6.5 MPa) in a suitable apparatus, sequentially, singly or repeatedly via one or more filters of decreasing pore size. Metal or polymer membranes or inorganic materials such as glass fibres are used, for example, for the extrusion. The process according to the invention permits simple and rapid production of liposomes and emulsions for pharmaceutical, cosmetic or other applications. With the use of suitable apparatuses, corresponding dispersions can be produced on the production scale.
AIMS: Non-alcoholic fatty liver disease (NAFLD) has become a global epidemic. Excessive fibrogenesis, characterized by activation of hepatic stellate cells (HSCs), is a hallmark event in late stages of NAFLD. HSC activation is metabolically programmed by anaerobic glycolysis. In the present study we investigated the involvement of suppressor of variegation 3-9 homolog 1 (Suv39h1), a lysine methyltransferase, in NAFLD-associated liver fibrosis.
METHODS AND MATERIALS: Liver fibrosis was induced by feeding the mice with a methionine-and-choline deficient (MCD) diet for 8 weeks.
RESULTS: We report that germline deletion of Suv39h1 attenuated liver fibrosis in mice fed an MCD diet. In addition, HSC conditional deletion of Suv39h1 similarly ameliorated liver fibrosis in the NAFLD mice. Interestingly, co-culturing with hepatocytes exposed to palmitate promoted glycolysis in wild type HSCs but not in Suv39h1 deficient HSCs. Mechanistically, Suv39h1 facilitated the recruitment of hypoxia induced factor (HIF-1α) to stimulate the transcription of hexokinase 2 (HK2) in HSCs thereby enhancing glycolysis. Importantly, a positive correlation between Suv39h1, HK2, and myofibroblast markers was identified in liver specimens from NAFLD patients.
SIGNIFICANCE: In conclusion, our data identify a novel pathway that contributes to the liver fibrosis and points to the possibility of targeting Suv39h1 for the intervention of liver fibrosis in NAFLD.
Voltage-dependent calcium channels (Cav1) contribute to T-cell activation. The inventors previously showed that Th2 cells co-express Cav1.2 and Cav1.3 calcium channels acting in a non-redundant and concerted way to initiate early TCR-driven calcium influx required for cytokine production and Th2-cell functions. While they have demonstrated that both channels have to be present on the same T-cell to induce allergic asthma, how these channels are regulated under TCR engagement is yet unknown. They investigated the relationship between PKCα and the Cav1.2/Cav1.3 duo channels in Th2 cells. They showed that PKC activation was sufficient to trigger Cav1-dependent calcium response and Th2 cytokine production. Cav1 channels, and especially Cav1.3, expression increased at the cell membrane of Th2 cells upon TCR stimulation and PKCα selectively associated with Cav1.3 upon activation. They showed that PKCα antisense oligonucleotides (PKCα-AS) decreased Th2-cell functions and were beneficial in active and passive models of Th2-mediated airway inflammation induced by OVA. Altogether these results show that PKCα by interacting selectively with Cav1.3 after TCR engagement regulates Cav1.2/Cav1.3 duo-dependent calcium signaling and probably by this way impairs Th2-cell functions and their potential to mediate inflammation.